stockrowDanaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
Follow DHR
Alert me
Danaher Corporation (DHR) Revenue
Danaher Corporation's revenue for fiscal 2025 was $24.6B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $25.6B. Over the past ten years it has ranged from $14.4B (fiscal 2015) to $26.6B (fiscal 2022); the current reading is higher than 82% of that period. Danaher Corporation ranks 2nd of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $24.6B | 2.90% |
| FY2024 | $23.9B | (0.06%) |
| FY2023 | $23.9B | (10.33%) |
| FY2022 | $26.6B | 7.42% |
| FY2021 | $24.8B | 11.30% |
| FY2020 | $22.3B | 24.42% |
| FY2019 | $17.9B | 5.06% |
| FY2018 | $17.0B | 9.86% |
| FY2017 | $15.5B | (8.08%) |
| FY2016 | $16.9B | 16.97% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $6.6B | 4.61% |
| Jun 2026 | $6.3B | 5.28% |
| Mar 2026 | $6.0B | (12.97%) |
| Dec 2025 | $6.8B | 12.97% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TMO Thermo Fisher Scientific Inc. compare | $47.4B |
| DHR Danaher Corporation | $25.6B |
| IQV IQVIA Holdings Inc. compare | $17.3B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation compare | $5.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.7B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.9B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on DHR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement